The short version of synthetic peptide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-14 and is reviewed periodically as new material appears.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
=== Bulk nanostructured materials === Some bulk materials contain features on the nanoscale, including nanocomposites, nanocrystalline materials, nanostructured films, and nanotextured surfaces. Box-shaped graphene (BSG) nanostructure is an example of 3D nanomaterial. BSG nanostructure has appeared after mechanical cleavage of pyrolytic graphite. This nanostructure is a multilayer system of parallel hollow nanochannels located along the surface and having quadrangular cross-section. The thickness of the channel walls is approximately equal to 1 nm. The typical width of channel facets makes about 25 nm.
Horning (1917–2020), American biochemist and pioneer of chromatography who developed new techniques for studying drug metabolism Benjamin Hsiao (born 1958), Taiwanese American chemist working to understand the structural, morphological development and manipulation of complex polymer systems Linda Hsieh-Wilson (PhD 1996), American chemist known for work in chemical neurobiology on understanding the structure and function of carbohydrates in the nervous system Heinrich Hubert Maria Josef Houben (1875–1940), German organic chemist known for work on ketone synthesis, terpenes, and camphor Coenraad Johannes van Houten (1801–1887), Dutch chemist and chocolate maker who invented cocoa powder Amir H. Hoveyda (PhD 1986), American chemist, particularly noted for developing catalysts for stereoselective olefin metathesis Marcia Huber (PhD 1985), American chemical engineer known for modeling the thermophysical properties of fluids Robert Huber (born 1937), German chemist known for crystallizing an intramembrane protein important in photosynthesis, 1988 Nobel Prize in chemistry Catherine T. Hunt (born 1955), American chemist who worked on nuclear magnetic resonance and became president of the American Chemical Society
=== Genomic Architecture and Risk of Abdominal Obesity === In addition to the visible changes in adipose tissue associated with obesity, recent research indicates that the risk of developing abdominal obesity and cardiometabolic alterations also depends on the 3D organization of the genome in subcutaneous adipose tissue. Single‑cell epigenomic studies have shown that many genetic variants associated with abdominal fat distribution (measured as WHRadjBMI) are preferentially located in active genomic regions of adipocytes. These regions display low levels of DNA methylation and belong to the so‑called A compartment, which is characterized by higher gene activity. These findings suggest that adipocytes in subcutaneous adipose tissue play a key role in mediating the genetic risk associated with abdominal obesity.
Sources: en.wikipedia.org
== Relative bioavailability and bioequivalence == In pharmacology, relative bioavailability measures the bioavailability (estimated as the AUC) of a formulation (A) of a certain drug when compared with another formulation (B) of the same drug, usually an established standard, or through administration via a different route. When the standard consists of intravenously administered drug, this is known as absolute bioavailability (see above).
The Australian Pharmaceutical Formulary (APF) is the national formulary used by pharmacists in Australia, compiled by the Pharmaceutical Society of Australia. New editions of the APF are released every few years, with the latest edition being the 25th.
== History == The discovery of nanocellulosic materials can be traced back to late 1940s studies on the hydrolysis of cellulose fibers. Eventually it was noticed that cellulose hydrolysis seemed to occur preferentially at some disordered intercrystalline portions of the fibers. This led to the obtention of colloidally stable and highly crystalline nanorods particles. These particles were first referred to as micelles, before being given multiple names including cellulose nanocrystals (CNCs), nanocrystalline cellulose (NCC), or cellulose (nano)whiskers, though this last term is less used today. Later studies by O. A. Battista showed that in milder hydrolysis conditions, the crystalline nanorods stay aggregated as micron size objects. This material was later referred to as microcrystalline cellulose (MCC) and commercialised under the name Avicel by FMC Corporation.
Well-being changes throughout the lifespan as individuals transition from childhood through adolescence and adulthood to old age, reflecting factors such as educational and occupational responsibilities, family life, financial stability, and health. Well-being tends to decline from childhood until around age 40 globally. There are region-specific differences for the second part of life: some regions see a further decline towards old age, while the level remains stable in others and increases in some. There is little gender difference in well-being in most countries. Digital technologies, such as the internet and artificial intelligence, influence the well-being of individuals in various areas, such as information access, social relationships, work-life balance, and health. The effects are mixed, including benefits, like new learning opportunities, and risks, like social media addiction. In many areas, a proper understanding of the uses and dangers of a technology is essential for avoiding its potential harmful effects.
Sources: en.wikipedia.org
== Further reading == Aziz, Nusrate; Asadullah, M Niaz (2017). "Military spending, armed conflict and economic growth in developing countries in the post–Cold War era". Journal of Economic Studies. 44 (1): 47–68. Bartel, Fritz (2022). The Triumph of Broken Promises: The End of the Cold War and the Rise of Neoliberalism. Harvard University Press. ISBN 9780674976788. Henriksen, Thomas H. (2017). Cycles in US Foreign Policy Since the Cold War. Palgrave Macmillan. Jones, Bruce D.; Stedman, Stephen John (2017). "Civil Wars & the Post–Cold War International Order". Dædalus. 146 (4): 33–44. Menon, Rajan; Rumer, Eugene B., eds. (2015). Conflict in Ukraine: The Unwinding of the Post–Cold War Order. MIT Press. Peterson, James W. (2017). Russian-American relations in the post–Cold War world. Oxford UP. Sakwa, Richard (2017). Russia against the Rest: The Post–Cold War Crisis of World Order. Cambridge UP. p. 362. Wood, Luke B. (2017). "The politics of identity and security in post–Cold War Western and Central Europe". European Politics and Society. 18 (4): 552–556.
== Clinical significance == The multiple roles of moonlighting proteins complicates the determination of phenotype from genotype, hampering the study of inherited metabolic disorders. The complex phenotypes of several disorders are suspected to be caused by the involvement of moonlighting proteins. The protein GAPDH has at least 11 documented functions, one of which includes apoptosis. Excessive apoptosis is involved in many neurodegenerative diseases, such as Huntington's, Alzheimer's, and Parkinson's as well as in brain ischemia. In one case, GAPDH was found in the degenerated neurons of individuals who had Alzheimer's disease. Although there is insufficient evidence for definite conclusions, there are well documented examples of moonlighting proteins that play a role in disease. One such disease is tuberculosis. One moonlighting protein in M. tuberculosis has a function which counteracts the effects of antibiotics. Specifically, the bacterium gains antibiotic resistance against ciprofloxacin from overexpression of glutamate racemase in vivo. GAPDH localized to the surface of pathogenic mycobacteria has been shown to capture and traffic the mammalian iron carrier protein transferrin into cells resulting in iron acquisition by the pathogen.
In cellular biology, the Wnt signaling pathways are a group of signal transduction pathways which begin with proteins that pass signals into a cell through cell surface receptors. The name Wnt, pronounced "wint", is a portmanteau created from the names Wingless and Int-1. Wnt signaling pathways use either nearby cell-cell communication (paracrine) or same-cell communication (autocrine). They are highly evolutionarily conserved in animals, which means they are similar across animal species from fruit flies to humans. Three Wnt signaling pathways have been characterized: the canonical Wnt pathway, the noncanonical planar cell polarity pathway, and the noncanonical Wnt/calcium pathway. All three pathways are activated by the binding of a Wnt-protein ligand to a Frizzled family receptor, which passes the biological signal to the Dishevelled protein inside the cell. The canonical Wnt pathway leads to regulation of gene transcription, and is thought to be negatively regulated in part by the SPATS1 gene. The noncanonical planar cell polarity pathway regulates the cytoskeleton that is responsible for the shape of the cell. The noncanonical Wnt/calcium pathway regulates calcium inside the cell. Wnt signaling was first identified for its role in carcinogenesis, then for its function in embryonic development. The embryonic processes it controls include body axis patterning, cell fate specification, cell proliferation and cell migration. These processes are necessary for proper formation of important tissues including bone, heart and muscle.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.